| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jason C G Halford, Joanne A Harrol. 5-HT(2C) receptor agonists and the control of appetite. Handbook of experimental pharmacology. issue 209. 2012-04-25. PMID:22249823. |
lorcaserin, a selective 5-ht(2c) receptor agonist, is a novel anti-obesity agent that reduces both energy intake and body weight. |
2012-04-25 |
2023-08-12 |
Not clear |
| Kathryn M Hurren, Helen D Berli. Lorcaserin: an investigational serotonin 2C agonist for weight loss. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 68. issue 21. 2012-02-07. PMID:22011982. |
lorcaserin: an investigational serotonin 2c agonist for weight loss. |
2012-02-07 |
2023-08-12 |
Not clear |
| Kathryn M Hurren, Helen D Berli. Lorcaserin: an investigational serotonin 2C agonist for weight loss. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 68. issue 21. 2012-02-07. PMID:22011982. |
the pharmacology, pharmacokinetics, and adverse effects of the selective serotonin (5-ht) agonist lorcaserin are reviewed, with an emphasis on efficacy and safety data from phase iii clinical trials. |
2012-02-07 |
2023-08-12 |
Not clear |
| Renger F Witkam. Current and future drug targets in weight management. Pharmaceutical research. vol 28. issue 8. 2011-12-05. PMID:21181547. |
a number of new preparations, including combinations of the existing drugs topiramate plus phentermine, bupropion plus naltrexone, and the selective 5-ht(2c) agonist lorcaserin have recently been filed for approval. |
2011-12-05 |
2023-08-12 |
human |
| Meredith C Fidler, Matilde Sanchez, Brian Raether, Neil J Weissman, Steven R Smith, William R Shanahan, Christen M Anderso. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. The Journal of clinical endocrinology and metabolism. vol 96. issue 10. 2011-11-18. PMID:21795446. |
lorcaserin is a novel selective agonist of the serotonin 2c receptor. |
2011-11-18 |
2023-08-12 |
Not clear |
| Nicholas T Bello, Nu-Chu Lian. The use of serotonergic drugs to treat obesity--is there any hope? Drug design, development and therapy. vol 5. 2011-11-15. PMID:21448447. |
sibutramine is a serotonin and norepinephrine reuptake inhibitor, whereas lorcaserin is a selective 5ht(2c) receptor agonist. |
2011-11-15 |
2023-08-12 |
Not clear |
| Edward D Levin, Joshua E Johnson, Susan Slade, Corinne Wells, Marty Cauley, Ann Petro, Jed E Ros. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. The Journal of pharmacology and experimental therapeutics. vol 338. issue 3. 2011-10-31. PMID:21636655. |
lorcaserin, a selective 5-hydroxytryptamine(2c) (5-ht(2c)) agonist, has been shown to facilitate weight loss in obese populations. |
2011-10-31 |
2023-08-12 |
rat |
| Edward D Levin, Joshua E Johnson, Susan Slade, Corinne Wells, Marty Cauley, Ann Petro, Jed E Ros. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. The Journal of pharmacology and experimental therapeutics. vol 338. issue 3. 2011-10-31. PMID:21636655. |
these studies support development of the 5-ht(2c) agonist lorcaserin to aid tobacco smoking cessation. |
2011-10-31 |
2023-08-12 |
rat |
| André M Faria, Marcio C Mancini, Maria Edna de Melo, Cintia Cercato, Alfredo Halper. [Recent progress and novel perspectives on obesity pharmacotherapy]. Arquivos brasileiros de endocrinologia e metabologia. vol 54. issue 6. 2011-10-03. PMID:20857056. |
this review will discuss the efficacy and safety of these compounds, which include lorcaserin (selective serotonin 5-ht2c agonist), tesofensine (triple monoamine reuptake inhibitor), liraglutide (glp-1 analogue) and cetilistat (gastrointestinal lipase inhibitor), as well as the combination therapies of bupropion/naltrexone, bupropion/zonisamide, phentermine/topiramate and pramlintide/metreleptin. |
2011-10-03 |
2023-08-12 |
Not clear |
| Harold E Bay. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert review of cardiovascular therapy. vol 9. issue 3. 2011-07-26. PMID:21438803. |
lorcaserin is a selective 5-hydroxytryptamine receptor 2c agonist developed as a weight-loss drug. |
2011-07-26 |
2023-08-12 |
Not clear |
| M J Shram, K A Schoedel, C Bartlett, R L Shazer, C M Anderson, E M Seller. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clinical pharmacology and therapeutics. vol 89. issue 5. 2011-06-21. PMID:21412231. |
evaluation of the abuse potential of lorcaserin, a serotonin 2c (5-ht2c) receptor agonist, in recreational polydrug users. |
2011-06-21 |
2023-08-12 |
Not clear |
| M J Shram, K A Schoedel, C Bartlett, R L Shazer, C M Anderson, E M Seller. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clinical pharmacology and therapeutics. vol 89. issue 5. 2011-06-21. PMID:21412231. |
lorcaserin is a selective and potent serotonin 2c receptor subtype (5-ht(2c)) agonist under development for the treatment of obesity. |
2011-06-21 |
2023-08-12 |
Not clear |
| L M Redman, E Ravussi. Lorcaserin for the treatment of obesity. Drugs of today (Barcelona, Spain : 1998). vol 46. issue 12. 2011-06-09. PMID:21589947. |
lorcaserin is a novel selective agonist of the 5-ht(2c) receptor for weight loss therapy. |
2011-06-09 |
2023-08-12 |
Not clear |
| L M Redman, E Ravussi. Lorcaserin for the treatment of obesity. Drugs of today (Barcelona, Spain : 1998). vol 46. issue 12. 2011-06-09. PMID:21589947. |
preclinical and clinical studies indicate lorcaserin is well tolerated and not associated with cardiac valvulopathy or pulmonary hypertension suggesting that lorcaserin is a selective 5-ht(2c) receptor agonist and has little or no activation of the 5-ht(2b) and 5-ht(2a) receptors, respectively. |
2011-06-09 |
2023-08-12 |
Not clear |
| Corby K Martin, Leanne M Redman, Jinkun Zhang, Matilde Sanchez, Christen M Anderson, Steven R Smith, Eric Ravussi. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. The Journal of clinical endocrinology and metabolism. vol 96. issue 3. 2011-05-23. PMID:21190985. |
lorcaserin, a 5-ht(2c) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. |
2011-05-23 |
2023-08-12 |
Not clear |
| Corby K Martin, Leanne M Redman, Jinkun Zhang, Matilde Sanchez, Christen M Anderson, Steven R Smith, Eric Ravussi. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. The Journal of clinical endocrinology and metabolism. vol 96. issue 3. 2011-05-23. PMID:21190985. |
lorcaserin, a selective 5-hydroxytryptamine (5-ht)(2c) receptor agonist, reduces body weight. |
2011-05-23 |
2023-08-12 |
Not clear |
| Jason C G Halford, Emma J Boyland, John E Blundell, Tim C Kirkham, Joanne A Harrol. Pharmacological management of appetite expression in obesity. Nature reviews. Endocrinology. vol 6. issue 5. 2010-07-30. PMID:20234354. |
these currently include glucagon-like peptide-1 analogs such as liraglutide, an amylin analog davalintide, the 5-ht(2c) receptor agonist lorcaserin, the monoamine re-uptake inhibitor tesofensine, and a number of combination therapies such as pramlintide and metreleptin, bupropion and naltrexone, phentermine and topiramate, and bupropion and zonisamide. |
2010-07-30 |
2023-08-12 |
Not clear |
| Steven R Smith, Neil J Weissman, Christen M Anderson, Matilde Sanchez, Emil Chuang, Scott Stubbe, Harold Bays, William R Shanaha. Multicenter, placebo-controlled trial of lorcaserin for weight management. The New England journal of medicine. vol 363. issue 3. 2010-07-29. PMID:20647200. |
lorcaserin is a selective serotonin 2c receptor agonist that could be useful in reducing body weight. |
2010-07-29 |
2023-08-12 |
Not clear |
| Harold E Bay. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. Expert review of cardiovascular therapy. vol 7. issue 11. 2010-02-23. PMID:19900026. |
this review examines: the mechanisms by which serotonergic pathways improve adiposity and adiposopathy; historical data and perspective regarding the efficacy and safety of prior 5-ht agonists; speculation regarding future paradigms in treating adiposopathy; and why lorcaserin may prove to be a safe and generally well-tolerated agent that not only improves the weight of patients, but also improves the health of patients. |
2010-02-23 |
2023-08-12 |
Not clear |
| Paul J Fletcher, Maria Tampakeras, Judy Sinyard, Abdelmalik Slassi, Methvin Isaac, Guy A Higgin. Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice. Neuropharmacology. vol 57. issue 3. 2009-11-27. PMID:19501602. |
initially this study compared older 5-ht(2c) agonists mcpp and mk212, to newer, apparently more selective compounds: ro 60-0175, way161503, cp809,101 and lorcaserin (apd356) on motor activity in wild-type, and 5-ht(2c) receptor knockout mice. |
2009-11-27 |
2023-08-12 |
mouse |